B+
Bull case
25%
Probability
Target price
$1.35
Analysis reference price unavailable
Analysis 2026-05-04 · RankAlpha Sentiment Codex
GDTC
CytoMed TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The best constructive read is that the March 31, 2026 company update did provide tangible operating hooks: ANGELICA had treated six patients, dose escalation was moving forward, management still targeted Phase I completion in 2026, and a Malaysia IND submission was targeted before June 2026. With an equity value around the low teens of millions, even modest clinical or regulatory confirmation could move the stock disproportionately.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
Cash and bank balances fell to US$1.63 million at December 31, 2025 from US$3.87 million a year earlier, elevating near-term financing and runway risk.
Momentum
64
Value
46
Sentiment
82
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.95 · Bull $1.35 · Bear $0.50Analysis 2026-05-04; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-04 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Why
Momentum64 · Δ7d -
Value46 · Δ7d 0.0
Sentiment82 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite.
Contradictions & invalidation
- • Cash and bank balances fell to US$1.63 million at December 31, 2025 from US$3.87 million a year earlier, elevating near-term financing and runway risk.
- • Clinical execution remains early-stage: ANGELICA is still in Phase I dose escalation and the Malaysia CTM-GDT program still needs an IND submission and regulatory progress.
- • The bearish read is that FY2025 results highlighted a tighter balance sheet, with cash down to US$1.63 million and audited net loss widening to US$3.11 million.
Catalyst clock
2026-05-22
Post-results runway scrutiny and May 22 AGM financing authority
Lead driver: Sentiment · See AI snapshot
Momentum
64
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
46
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
-0.0
Sentiment
82
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 64.3 / Value 46.5 / Sentiment 82.2
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-04. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$0.95
Analysis reference price unavailable
Analysis 2026-05-04 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.50
Analysis reference price unavailable
Analysis 2026-05-04 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$10.72M
Beta
-
Shares Out
11.83M
P/E (TTM) · Derived
-3.5
P/S (TTM)
90.31
P/FCF (TTM) · Derived
-3.25
Rev YoY
-
EPS YoY
-106.1%
Gross Margin
-278.4%
Op Margin
-1434.5%
Net Debt
-$1.25M
Current Ratio
5.17
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data